Sanofi, Eureka ink $1B myeloma drug licensing agreement

2021-07-13

Sanofi has signed an exclusive licensing agreement with Eureka Therapeutics and the Memorial Sloan Kettering Cancer Center for its G Protein Coupled Receptor Family C Group 5 Member D candidate for multiple myeloma for non-CAR use. Eureka and MSK will receive an upfront payment of an undisclosed amount, including potential development, regulatory and marketing milestone payments up to $1 billion.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.